Altimmune (NASDAQ:ALT) Trading 16.1% Higher – Should You Buy?

Altimmune, Inc. (NASDAQ:ALT) shares were up 16.1% during trading on Friday . The stock traded as high as $5.94 and last traded at $6.2470. Approximately 2,101,752 shares changed hands during trading, a decline of 62% from the average daily volume of 5,556,123 shares. The stock had previously closed at $5.38.

Analyst Ratings Changes

ALT has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Finally, Citizens Jmp lowered their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $16.60.

Altimmune Price Performance

The firm has a market capitalization of $600.48 million, a PE ratio of -5.40 and a beta of 0.04. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. The stock has a fifty day moving average price of $4.54 and a 200-day moving average price of $4.11.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.08. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. Sell-side analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling at Altimmune

In other news, Director Jerome Benedict Durso purchased 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the transaction, the director owned 12,500 shares in the company, valued at $51,625. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Gill acquired 12,500 shares of Altimmune stock in a transaction on Tuesday, December 23rd. The shares were bought at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the transaction, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 30,527 shares of company stock valued at $125,278. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP raised its stake in Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after acquiring an additional 1,559,562 shares in the last quarter. Vanguard Group Inc. grew its stake in Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after buying an additional 1,206,514 shares during the last quarter. Federated Hermes Inc. lifted its stake in Altimmune by 387.7% in the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock valued at $3,543,000 after buying an additional 727,731 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Altimmune in the third quarter valued at approximately $2,204,000. Finally, Bank of America Corp DE grew its position in shares of Altimmune by 155.2% during the second quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock worth $2,771,000 after acquiring an additional 435,467 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.